Amplistar Inc.
This article was originally published in Start Up
Executive Summary
Amplistar is pursuing an entirely new approach to cancer diagnostics, one it hopes will allow both earlier and more effective detection of the diseases. Rather than measuring tumor marker proteins (like PSA for prostate cancer, or CA-125 for ovarian cancer), Amplistar aims to identify those tumor targets that produce an immune response in the body. The company believes that antibodies generated in response to tumor antigens may be detectable in the blood earlier than tumor marker proteins.
You may also be interested in...
Cancer Diagnostics
New hunters of diagnostic biomarkers hope to improve cancer diagnosis. They envision biomarkers that will allow more accurate disease-stage monitoring, more effective choice of therapy and, ultimately, the development of therapies themselves. Despite the plethora of new technologies, tools, and genomic data, however, cancer-specific markers have provent obe difficult beasts to catch.
Shionogi's Oral COVID Drug Set For Global Access Through MPP
Agreement with UN-affiliated body set to expand global availability in lower income countries of Japanese firm’s protease inhibitor, which has faced approval road bumps at home but now looks set to move forward on positive new Phase III data.
Medicare CED Update Targets Study ‘Efficiency,’ But May Not Ease Data Collection Burden
It's not clear that the proposed revisions and additions to the Centers for Medicare and Medicaid Services’ existing coverage with evidence development study design requirements would address what some experts view as a program failure – the fact that sponsors of the vast majority of technologies subject to CED have not generated the data CMS is looking for.